Rowan Chapman Sells 4,366 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 4,366 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $243.10, for a total transaction of $1,061,374.60. Following the transaction, the director owned 5,777 shares in the company, valued at approximately $1,404,388.70. This represents a 43.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Natera Trading Down 1.5%

Shares of NASDAQ:NTRA traded down $3.61 during trading on Tuesday, reaching $235.53. The stock had a trading volume of 1,077,565 shares, compared to its average volume of 1,540,875. The firm’s 50-day simple moving average is $202.57 and its 200 day simple moving average is $175.16. Natera, Inc. has a one year low of $125.38 and a one year high of $246.90. The company has a market capitalization of $32.58 billion, a P/E ratio of -102.85 and a beta of 1.63.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s revenue was up 34.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) EPS. Equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Siemens Fonds Invest GmbH lifted its holdings in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after buying an additional 54 shares during the period. Guided Capital Wealth Management LLC boosted its position in Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after purchasing an additional 66 shares in the last quarter. BOKF NA grew its stake in shares of Natera by 1.9% during the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after purchasing an additional 69 shares during the period. Silvant Capital Management LLC lifted its stake in shares of Natera by 0.5% in the 3rd quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock valued at $2,171,000 after purchasing an additional 70 shares during the period. Finally, Main Management ETF Advisors LLC grew its position in Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after buying an additional 72 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on NTRA shares. Wells Fargo & Company raised their price target on Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a report on Friday, November 7th. Morgan Stanley increased their price objective on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 target price on the stock in a research report on Monday, October 27th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Natera from $240.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 25th. Fifteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $225.29.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.